Search the Newsreel

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

Levi & Korsinsky has launched an investigation into potential securities law violations by Phathom Pharmaceuticals (PHAT) after the company issued a revised FY 2026 revenue outlook that fell below analyst expectations, causing its shares to decline. The law firm is encouraging investors who lost …

Alphatec (ATEC) Q2 Earnings Lag Estimates

Alphatec (ATEC) Earnings Date and Reports 2026

Alphatec Holdings (NASDAQ: ATEC) lifts spine revenue, refinances debt load

Alphatec Holdings, Inc. (NASDAQ: ATEC) generated $764.15 million in revenue last year, primarily from its Spinal Surgery Implants segment. This segment was also its top performer the previous year, contributing $611.56 million. The United States was the largest geographical contributor, accounting for $716.14 million …

Alphatec Raises 2026 Adjusted EBITDA Guidance to About $140M

Accumulate Paradeep Phosphates; target of Rs 158: Prabhudas Lilladher

Canadian Phosphate (ASX:CP8) Takes Full Control of Utah’s Diamond Mountain Deposit

Phathom Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $23.1, Implies 98% Upside

Phathom Pharmaceuticals, Inc.'s stock (PHAT) has seen its average 12-month price target reduced from $23.7 to $23.1 by 10 analysts, with individual forecasts ranging from $13 to $29 per share. This new target suggests a potential upside of approximately 98% based on the July …

925,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Perceptive Advisors LLC

Alphatec (ATEC) Stock May Trade Below Fair Value On Sales Growth

Enterprise value to revenue forward of Alphatec Holdings, Inc. – NASDAQ:ATEC

This article focuses solely on the enterprise value to revenue forward for Alphatec Holdings, Inc. (NASDAQ: ATEC). The content appears to be a financial data point from TradingView, indicating a specific period's value, change, and percentage change for this metric. No additional financial analysis …

Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PHAT) 2026-08-01

Phathom Pharmaceuticals (PHAT) achieved its first-ever positive operating profit and cash from operations in Q2 2026, with revenue growing 88% year-over-year to $74.3 million. Despite this, full-year revenue guidance was slightly lowered due to prior authorization friction for Voquezna, and the company anticipates using …

Paradeep Phosphates Q1FY27 net profit rises 24% to ₹393 crore

Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough

Phathom Pharmaceuticals (PHAT) stock slid 3.1% to US$8.75 despite reporting its first quarter of operating profit on a cash basis, excluding stock-based compensation, with revenue of US$74.3m. This breakthrough included US$1.6m of positive operating cash flow, narrowing its GAAP net loss to US$17.6m. While …

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals

SueWallSt, powered by Levi & Korsinsky LLP, has launched an investigation into Phathom Pharmaceuticals (NASDAQ: PHAT) regarding potential securities law violations. The investigation focuses on Phathom's FY 2026 revenue guidance, which was initially maintained at $320 million to $345 million but later cut to …

Phathom Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Phathom Pharmaceuticals (NASDAQ: PHAT) had approximately 380 employees worldwide as of March 2026, marking a 205.2% growth since 2023 but a 5.4% year-over-year decrease. The company is actively hiring, with 49 job postings in 2026 and an accelerating hiring velocity of 111 new roles …

Phathom Pharmaceuticals Down Over 19%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk

Phathom Pharmaceuticals experienced a significant drop of over 19% in early trading, marking its largest percentage decrease since May 2025. The stock is currently trading at $10.15, down $2.43 from its previous close, with trading volume significantly higher than its 50-day average. This decline …

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals, Inc. (PHAT) reported break-even earnings per share for Q2 2026, outperforming the Zacks Consensus Estimate of a $0.06 loss. The company also surpassed revenue expectations with $74.27 million, compared to $39.5 million a year ago. Despite this positive earnings surprise, the stock …

Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4

Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2026 MANAGEMENT VIEW * "For the first time in Phathom's history and ahead of our guidance, we generated positive operating profit in Q2, excluding stock-based compensation." (CEO, President & Director Steven Basta) * "For full year 2026, …

Canadian Phosphate issues new shares and confirms compliance with disclosure rules

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

Levi & Korsinsky, LLP has announced an investigation into Phathom Pharmaceuticals (PHAT) following a reduction in its FY 2026 revenue guidance. The firm is encouraging investors who suffered losses after the company lowered its previously reaffirmed revenue outlook from $320 million-$345 million to $300 …

Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ...

Phathom Pharmaceuticals Inc (PHAT) reported its first-ever positive operating profit and cash from operations in Q2 2026, with revenue growing 88% year-over-year to $74.3 million. Despite success, the company faces "friction" in prior authorizations for Voquezna, leading to a slight reduction in full-year 2026 …

Earnings call transcript: Phathom posts Q2 2026 revenue beat, shares fall premarket

Phathom Pharmaceuticals reported an 88% year-over-year revenue increase in Q2 2026, reaching $74.3 million, and achieved positive operating profit earlier than expected. Despite these strong operational results and a slight revenue beat, the company's shares fell 8.93% in premarket trading due to concerns over …

Phathom Pharmaceuticals Releases Q2 2026 Financial Results

Phathom Pharmaceuticals reported breakeven adjusted results for Q2 2026, exceeding analyst expectations with revenue of $74.3M, an 88.0% increase year-over-year. The company's flagship product, VOQUEZNA, continued its strong commercial traction with 325,000 prescriptions filled in the quarter and 1.7M total prescriptions to date. Management …

Phathom Pharmaceuticals posts Q2 2026 revenue $74.3M, narrows net loss to $17.6M

Phathom Pharmaceuticals reported strong Q2 2026 results, with net revenues reaching $74.3 million, an 88% increase year-over-year, and a narrowed net loss of $17.6 million. The company also announced plans to initiate a Phase 3 trial for VOQUEZNA in Non-Erosive GERD and completed enrollment …

Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.00 per Share, vs. FactSet Est of $-0.19

Phathom Pharmaceuticals, Inc. announced its Q2 adjusted EPS was $0.00 per share, significantly outperforming FactSet's estimate of $-0.19. The company, which specializes in treatments for gastrointestinal diseases, posted these results on July 30, 2026. This financial update follows news of narrowing adjusted losses and …

Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Expectations By $0.02 EPS

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Down on Disappointing Earnings

Rama Phosphates Standalone June 2026 Net Sales at Rs 224.80 crore, up 18.12% Y-o-Y

Levi & Korsinsky Announces Investigation of Securities Claims Against Phathom Pharmaceuticals, Inc. (PHAT)

Levi & Korsinsky has launched an investigation into Phathom Pharmaceuticals, Inc. (PHAT) due to potential violations of federal securities laws. This follows Phathom Pharmaceuticals cutting its FY 2026 revenue guidance by $20 million just weeks after reaffirming higher projections. The investigation seeks to help …

BlackRock (PHAT) discloses 4.38M-share passive stake in Pharmaceuticals Inc

BlackRock, Inc. has publicly disclosed a passive ownership stake of 4,378,647 common shares in Phathom Pharmaceuticals Inc. (PHAT), representing 5.5% of the company's common stock. This filing, a Schedule 13G, indicates BlackRock holds sole voting power over 4,293,374 shares and sole dispositive power over …

Phathom Pharmaceuticals Inc (PHAT) Institutional Confidence

Phathom Pharmaceuticals Inc. has an institutional shareholding score of 7.00, placing it 50th out of 155 in the Pharmaceuticals industry. Institutional shareholding recently increased by 13.56% quarter-over-quarter, reaching 87.57%. Key institutional investors include Frazier Life Sciences Management, Millennium Management LLC, and BlackRock Institutional Trust …

Paradeep Phosphates shares gains 2% on strong Q1; board approves ₹250cr capex for AlF₃ plant

Paradeep Phosphates shares rise 12.5% as Q1 net profit jumps 24%

Paradeep Phosphates shares jump 15% on strong Q1 results, Rs 250-crore AlF3 plant approval

Paradeep Phosphates shares jump 13% after strong Q1 earnings, ₹250 crore expansion plan